Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Theranostics Market Report by Disease Type (Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, and Others), Technology (Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others), and Region 2024-2032
Report Format: PDF+Excel | Report ID: SR112024A4501
Buy Now
Market Overview:
The global theranostics market size is projected to exhibit a growth rate (CAGR) of 9.1% during 2024-2032.
|
Report Attribute
|
Key Statistics
|
|---|---|
|
Base Year
|
2023
|
|
Forecast Years
|
2024-2032
|
|
Historical Years
|
2018-2023
|
| Market Growth Rate 2024-2032 | 9.1% |
Theranostics is a combination of various radioactive drugs and techniques used to diagnose, deliver therapy, and treat life-threatening illnesses. It is cost-effective and involves pharmacogenetics, proteomics, and biomarker profiling. It can be integrated with nanomedicine to target specific organs and tissues and improve patient-specific outcomes. Nowadays, researchers worldwide are developing new diagnostic and therapeutic agents for theranostics to personalize the treatment of cancer, reduce side effects of treatment, and improve the quality care of pharmacotherapy.
.webp)
The rising prevalence of cancer due to the increasing consumption of tobacco and alcohol, high body mass index (BMI), low nutrition intake, and lack of physical activity represents one of the main factors stimulating the market growth. Moreover, according to the World Health Organization (WHO), cancer is the second leading cause of death globally, out of which 70% of deaths occur in low and middle-income countries. This is encouraging health and governing agencies of several countries to increase awareness about the available medical treatments and improve the healthcare infrastructure, which is positively influencing the market growth. The escalating demand for personalized medicine is also bolstering the market growth. Apart from this, the integration of seamless, multiple imaging treatment technologies within a single nanoparticle to tackle pathologies is driving the market. Furthermore, the increasing approvals to produce theranostics and rising investments in research and development (R&D) activities are other factors anticipated to propel the growth of the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global theranostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on disease type, technology and end user.
Breakup by Disease Type:
- Neurological Disorders
- Cardiovascular Diseases
- Immunological Disorders
- Oncology Diseases
- Others
Breakup by Technology:
- Polymerase Chain Reaction
- Immunohistochemistry
- In-Situ Hybridization
- Sequencing
- Others
Breakup by End User:
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Units | US$ Billion |
| Segment Coverage | Disease Type, Technology, End User, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered | Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V., Thermo Fisher Scientific Inc. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
We expect the global theranostics market to exhibit a CAGR of 9.1% during 2024-2032.
The rising development of new diagnostic and therapeutic agents for theranostics for personalizing the treatment of cancer, reducing side effects of treatment, and improving the quality care of pharmacotherapy is primarily driving the global theranostics market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of cancer treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for theranostics.
Based on the disease type, the global theranostics market can be segmented into neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others. Currently, oncology diseases exhibit a clear dominance in the market.
Based on the technology, the global theranostics market has been bifurcated into polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others. Among these, polymerase chain reaction currently accounts for the majority of the total market share.
Based on the end user, the global theranostics market can be divided into hospitals and clinics, diagnostic laboratories, and others. Currently, hospitals and clinics hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More